A multi-center, double-blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment

Background There have been no mortality/morbidity endpoint studies with Iosartan in Chinese heart failure patients. The objective was to evaluate the effects of high-dose vs. low-dose Iosartan on clinical outcomes in Chinese subjects with heart failure.